KERX Financial Facts

Total operating expenses: 35.65M
Basic and diluted net loss per common share: -0.38
See Full Income Statement

Other liabilities: 75K
Total liabilities and stockholders' equity: 126.91M
See Full Balance Sheet

Keryx Biopharmaceuticals Inc. (KERX) Earnings

  |   Expand Research on KERX
Next EPS Date 3/12/15 *Est. EPS Growth Rate -100.0% *Last Qtr.
Average EPS % Beat Rate -38.9% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS +0.5% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
3/8/11 Q410 -$0.09-$0.06 -$0.03N/A$2.82M N/A Details
5/8/12 Q112 -$0.13-$0.12 -$0.01N/AN/A N/A Details
2/29/12 Q411 -$0.12-$0.14 +$0.02N/AN/A N/A Details
11/4/13 Q313 -$0.19-$0.11 -$0.08N/A$2.22M N/A Details
5/7/13 Q113 -$0.03-$0.01 -$0.02$7M$5.83M N/A Details
11/8/12 Q312 -$0.08-$0.07 -$0.01N/AN/A N/A Details
8/7/14 Q214 -$0.24-$0.25 +$0.01N/AN/A N/A Details
8/8/11 Q211 -$0.05-$0.03 -$0.02$5M$5M N/A Details